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Introduction
Standard treatment of epithelial ovarian cancer (EOC) generally consists of primary surgery, with the aim of complete cytoreduction, followed by six cycles of carboplatin and taxanes every three weeks (1) . In cases of comorbidity, the chemotherapeutic agents are often modified to avoid possible adverse effects. In some patients with low performance status and/or advanced disease, chemotherapy is given prior to surgery (neoadjuvant) (2) . Complete cytoreduction after primary surgery and the duration of the treatment-free interval (TFI) after completion of primary chemotherapy are independent prognostic factors for survival among EOC patients (3) .
Epithelial ovarian cancer recurs in up to 75% of patients, even those with complete cytoreduction after primary surgery (1) . After completion of primary treatment, patients undergo surveillance to detect recurrence and need for additional treatment. Tumors are considered platinum-sensitive when recurrence occurs at least six months after completion of primary chemotherapy, thus these patients generally receive platinum-based chemotherapy (PBC) as secondary treatment (4) . However, in the last few decades, improved survival has been observed among patients with recurrent EOC who undergo secondary cytoreductive surgery (SCS), during which the visible tumor once again is completely removed, followed by PBC compared with those who receive PBC alone (5) (6) (7) .
A German group, Arbeitsgemeinschaft Gyn€ akologische Onkologie (AGO), attempted to structure recommendations for SCS (AGO score) in the DESKTOP I (8) and II trials (9) . DESKTOP III (10) is an international, multicenter, randomized controlled trial (RCT) that aims to evaluate prospectively whether SCS followed by PBC improves survival in patients with recurrent EOC and a positive AGO score (9) when compared with those treated with PBC alone. Patients enrolled in DESKTOP III had to have complete cytoreduction after primary surgery, first recurrence at least six months after completion of primary PBC, and fewer than 500 mL ascites at recurrence. Enrollment into DESKTOP III is now closed, and results are expected soon. Results from another multicenter RCT, the GOG 213 trial (11), will also be published in the near future. The SOCceR trial (12) met with recruitment problems and was prematurely terminated. A retrospective, population-based Dutch study reported 72% complete secondary cytoreduction and a median overall survival (OS) of 51 months among these patients (13) .
In the Norwegian guidelines, criteria similar to those of AGO are recommended for selection of patients to SCS and PBC or PBC alone (since 2007); however, SCS may be offered to those preferably with localized disease, irrespective of TFI, and even for patients with TFI over 24 months with disseminated disease (7) . Using a population-adjusted clinical epidemiology (PACE) approach (14) , we aimed to investigate survival retrospectively among patients with recurrent, platinum-sensitive EOC who received SCS followed by PBC in comparison with those who received PBC alone. A further aim was to identify possible predictors of progression-free survival (PFS) in these groups.
Material and methods
The completeness of registration for solid tumors at the Cancer Registry of Norway (CRN) is close to 100% (15, 16) and problems of loss to follow up are avoided through regular updates from the National Population
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Registry and National Patient Registry (17) . The CRN evaluates the quality of the data from these sources (18) , thus enabling an efficient evaluation of treatment of cancer in Norway each year (19) .
From the CRN database, we identified all EOC patients in FIGO stages I-IV with primary diagnosis between 1 January 2002 and 31 December 2012 (n = 4131). Patients with non-EOC, synchronous cancer or other cancers prior to EOC diagnosis were excluded from the study. From this entire population of EOC patients, 3206 underwent primary surgery followed by chemotherapy. We included only patients with no visible residuals after primary surgery followed by PBC who experienced first recurrence after more than six months without ascites, and had performance status WHO = 0: in all, 397 patients met these criteria, which represents 10% of the entire population of 4131. Patients were separated into two treatment groups: (i) SCS and PBC (SCS+PBC group) when SCS was performed and PBC planned, and (ii) PBC alone (PBC group) when PBC was planned. Our inclusion criteria were in line with the DESKTOP III trial (10) with a positive AGO score (9) . The study cohort consists of 75 patients in the SCS+PBC group and 322 in the PBC group (Appendix S1, Figure 1 ).
Statistical analyses
All patients were followed from the date of first recurrence until the date of the outcome, the date of emigration or the end of study (31 December 2015), whichever came first. Two primary outcomes were defined: (i) PFS, calculated as the time from start of follow up to second recurrence or death and (ii) OS, the time from start of follow up to death.
Descriptive statistics are presented as numbers, proportions and mean/median where applicable. Differences in distribution between the two treatment groups were examined univariately using the standard Chi-square test (v 2 ). Survival curves are presented in traditional KaplanMeier plots. To compare the risk of experiencing the outcomes between the treatment groups, hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were estimated using multivariable Cox proportional hazards regression, adjusting for relevant confounding variables. A p-value <0.05 was regarded as significant. Analyses were performed using STATA version 14.2 (StataCorp, College Station, TX, USA).
Ethical approval
The Regional Committee for medical and health research ethics in Oslo, Norway, approved this project (number 2010/1575).
Results
The proportion of patients in the SCS+PBC group was evenly distributed throughout the enrollment years (data not shown). No patient from either treatment group was lost to follow-up. There was no difference in the distribution of FIGO stages between the SCS+PBC and the PBC group (p = 0.6). The majority of patients represented FIGO stages III: 36 (48%) vs. 179 (56%), respectively (Table 1 ). There were 55 (73%) EOC patients with serous histology in the SCS+PBC group, compared with 228 (71%) in the PBC group (p = 0.3, Table 1 ). Corresponding numbers for endometroid, mucinous, clear-cell and non-classified adenocarcinomas are shown in Table 1 . There were no differences in comorbidity between the two treatment groups (data not shown).
Age groups at first recurrence were equally represented in the two treatment groups (p = 0.2, Table 2 ). There were 48 (64%) patients in the SCS+PBC group with a TFI >24 months, vs. 155 (48%) patients in the PBC group (p = 0.04). Computed tomography was the predominantly used imaging method at recurrence. Nineteen (25%) patients in SCS+PBC group had disseminated lesions (more than three lesions) depicted on radiological images (16% missing) compared with 143 (44%) in the PBC group (37% missing), p = 0.001. Non-disseminated radiological lesions three or fewer lesions) were present in 104 patients (43 (57%) in the SCS+PBC and 61 patients (19%) in the PBC group (Table 2) . Secondary PBC was received by 90% of patients in each group and changes from planned PBC did not differ between treatment groups (p = 0.4, Table 2 ). All patients who received secondary PBC finished their treatment; adverse effects were few and did not differ between treatment groups (data not shown). Progression-free interval varied between the groups, with second recurrence being less common in the SCS+PBC group. At the end of follow up, 28 (37%) patients in the SCS+PBC group were alive without second recurrence compared with 29 (9%) in the PBC group (p < 0.001, Table 2 ).
Median PFS in the SCS+PBC group was two years (95% CI 1.42-2.69) compared with one year (95% CI 0.93-1.13) in the PBC group (Figure 2a) . Median OS in the SCS+PBC group was six years (95% CI 3.39 -right border not obtainable due to long survival) compared with two years (95% CI 1.90-2.56) in the PBC group (Figure 2b ). After adjustment for potential confounders (age, FIGO stage, TFI, histology and tumor grade), the hazard ratio (HR) was 0.45 (95% CI 0.32-0.62) for PFS and 0.50 (95% CI 0.32-0.70) for OS, in favor of the SCS+PBC group (Table 3) . Among the 75 patients in the SCS+PBC group, complete resection at SCS was achieved in 60 (80%). The remaining 15 (20%) patients had the following residuals: six patients had peritoneal lesions, three had organ metastases and in six we had no available information. Restricting analyses to patients with complete resection, we found further improvement in the survival estimates in favor of the SCS+PBC group (HR for The potential confounders are presented in Table S1 showing increase in HR for patients in age group ≥80 years, FIGO stage VI, and with mucinous or clear cell tumors and, not influenced by tumor grade. As to TFI, we observed improvement of PFS and OS being found for patients with a TFI of >24 months (HR for PFS = 0.42, 95% CI 0.30-0.59; HR for OS = 0.29, 95% CI 0.20-0.43).
Sensitivity analyses were done estimating multivariable Cox regression model and including radiological images as a confounding variable. The estimates remained largely unchanged. Analyses after excluding non-serous histology and/or all patients who did not receive PBC, showed similar estimates.
Distribution of radiological lesions prior to SCS and progression-free intervals to second recurrence (death or end of study) after SCS are summarized in Table 4 . Information on radiology prior to diagnosis of first recurrence was available for 51 patients with complete resection at SCS. The proportion of complete resection at SCS was higher among patients with non-disseminated radiological lesions (39/43, 90%) than those with disseminated lesions (12/19, 63%) ( Table 4) . OS among 51 patients with complete resection at SCS and with non-disseminated radiological lesions corresponded with a five-year survival rate of 77% (95% CI 0.57-0.89). Interestingly, the five-year survival rate for patients with disseminated radiological lesions and complete resection at SCS was 61%. For those in the PBC group with nondisseminated radiological lesions, the five-year survival rate was 40%, whereas for the others with disseminated radiological lesions or with residuals left at SCS or missing values, the five-year survival rate was >21% (Figure S1 ).
Discussion
Our retrospective, registry-based study demonstrated that EOC patients (all FIGO stages) with good performance status and with complete cytoreduction after primary surgery followed by PBC and first recurrence more than six months after completion of primary treatment, had improved OS and PFS when treated with SCS resulting in complete resection compared with either PBC alone or SCS with some visible residuals. This is in agreement with previous studies (5, 20) . The strength of the study is the long follow-up time, detailed, high-quality data on first and second recurrence, and continuous surveillance of patients without exclusions due to advanced age or loss to follow up. Indeed, loss to follow up can be an obstacle in international RCTs; the DESKTOP III trial (10) had an estimated 10% loss to follow up. Recruitment to international RCTs may be influenced by differences in healthcare systems between countries, private insurance coverage, and socioeconomic status, which could lead to selection bias. Patients treated with SCS who refuse to give informed consent to participate in a RCT could also introduce bias. Some RCTs are difficult to conduct (12) .
We used a PACE (14) approach to compare survival in two treatment groups. In this method, follow-up data are systematically gathered and evaluated without recruitment problems or exclusions due to age or poor health conditions. This is an advantage over RCTs, which have a tendency not to include elderly patients (21) , whereas all age groups are represented in our population-based study. This type of population-based clinical/epidemiological research is considered to be of high quality and to generate satisfactory evidence for clinical practice (22) , especially for fields in which RCTs are difficult to conduct (12) . With its complete, high-quality, population-based cancer registry, Norway is an ideal country for a PACE study. Moreover, as there is little difference in treatment among EOC patients due to the national healthcare system in Norway, and patients are followed throughout their lifetime at CRN, the PACE approach may contribute to the validation of SCS and PBC vs. PBC alone when compared with results from RCTs, thanks to the efficient collection of follow-up data at the CRN.
Our study is retrospective, with known limitations, and is not free from selection bias. In Norway, patients with first recurrence are usually referred to the gynecologic oncology department of a teaching hospital, where a multidisciplinary tumor board considers whether they should undergo SCS and PBC or PBC alone. Patients are selected to SCS and PBC based on a long TFI, the platinum sensitivity status, the presence of non-disseminated lesions in radiological images, lack of ascites, and good performance status (7) . These clinical criteria differ from those of the DESKTOP III study (10) with a positive AGO score (9) . Our study indicates that such selection led to a resection rate at SCS comparable to the results of others (13) . It seems that the treatment with SCS, providing complete cytoreduction, has a beneficial effect on OS and PFS compared with either the patients with residuals after SCS or those treated with PBC alone. Additionally, our finding of 61% five-year survival rate among patients from the SCS group whose radiological lesions were disseminated, may be interpreted as a positive result of SCS with complete resection. We identified patients in both groups for whom planned PBC was changed. The proportion of these patients did not differ between treatment groups and did not influence survival analyses substantially. We observed longer TFIs and a smaller proportion of disseminated radiological lesions in the SCS+PBC compared with the PBC group. TFI and well-defined, non-disseminated lesions seemed to predict longer PFS. To match the SCS+PBC and PBC groups, we used a Cox regression model including TFI as a confounding variable. The small number of identified confounders, presented in a simple, dichotomized way, is a weakness of this study.
Non-disseminated lesions in radiological images may reflect the resectability of a recurring tumor. Our observation of a higher proportion of non-disseminated lesions at first recurrence in the radiological images of the SCS+PBC group compared with PBC group, is in accordance with previous findings (20, 23) . However, patients with disseminated lesions at first recurrence were also present in the SCS+PBC group and showed improved five-year survival rate after complete resection. Conversely, we cannot explain why some patients from the PBC group with non-disseminated radiological lesions and long TFI were not treated with SCS. It is probable that lesions at difficult locations introduced high complication risks and the gynecologic oncologist did not recommend SCS+PBC. Unfortunately, in the hospital records obtained for many patients in our study, details were missing on the dissemination in the descriptions of radiological images at first recurrence. More patients in the PBC group than in the SCS+PBC group received radiotherapy or tamoxifen as tertiary treatment after second recurrence. The proportion of patients that received tertiary PBC after second recurrence was similar in both treatment groups, but there were more patients without second recurrence and alive at the end of follow up in the SCS+PBC group. Investigation of platinum sensitivity beyond second recurrence in the SCS+PBC and PBC groups should be evaluated in future studies. We presented the age of the patients at first recurrence in age-groups and observed that patients ≥80 years had a higher mortality in our cohort. This observation may contribute to the discussion about the increasing life expectancy and age-related problems in EOC (21) .
In agreement with previous studies, we observed a higher HR for mucinous, clear cell and non-classified adenocarcinomas in multivariable analyses (3, 24) . This finding could be explained by more aggressive biological activity of these tumors. However, examination of such aggressiveness was beyond the scope of this study.
It is not clear whether the better OS we observed in the SCS+PBC group was due to treatment only or also related to tumor biology (25) . However, identifying these factors was beyond the scope of this study. Other studies have indicated a possible association between longer TFI and improved PFS, which may be the case for patients treated with SCS and PBC (6, 26) .
Improved survival in our SCS+PBC group does not necessarily mean that survival would have been better for patients in the PBC group if they had first been treated with SCS. The role of SCS in recurrent ovarian cancer treatment has not been clearly defined, and conclusive evidence is lacking (6, (27) (28) (29) . The studies that indicated improved survival in patients with SCS treatment had a retrospective design and were criticized for possible selection bias, various types of follow up, use of different diagnostic methods for first recurrence, and different types of chemotherapy given in the SCS group and chemotherapy-alone group, which made the evaluation of the effect of SCS difficult (6, 29, 30) . In our study, follow up was uniform for all patients, with plausible precision of diagnoses of first and second recurrence. Moreover, chemotherapy was similar in both groups.
The results from RCTs (10,11) will hopefully contribute important information about treatment practice in patients with recurring EOC.
Conclusion
In selected EOC patients with no residuals after primary surgery and a recurrent, platinum-sensitive tumor, the complete resection of recurrent tumor at SCS improves PFS and OS. Our results suggest that long TFI and nondisseminated lesions (three or fewer lesions) on radiological images could be useful predictors of complete resection at SCS.
